New DAA's and Controversies in HCV: What Clinicians Need to Know
Recorded On: 09/07/2017
Two new HCV meds have been approved over the summer. This webinar is meant to provide an update on how these fit into current practice. We will also cover the ongoing controversy on the risk of HCC with DAA's and the recent Cochrane report on the benefits of HCV therapy.
Paul Y. Kwo (Moderator)
Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C. He has won multiple awards, both at the university, local, and national level.
Andrew J. Muir (Moderator)
Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.
Dr. Ioannou is an Associate Professor of Medicine at the University of Washington and the Director of Hepatology at the Veterans Affairs Puget Sound Healthcare System. He is also the co-Director of the Hepatitis C Innovation Team for the Veterans Affairs VISN 20. His research interests include understanding the response to antiviral treatment for hepatitis C and the long-term implications of antiviral treatment in large, real-world cohorts of patients.
Robert S. Brown, Jr
Dr. Brown is the Vice Chair of Transitions of Care and Clinical Chief of the Division of Gastroenterology and Hepatology, as well as a Gladys and Roland Harriman Professor of Medicine, at Weill Cornell Medical College in New York City. His research focuses on the clinical and cost outcomes of liver disease, in particular, viral hepatitis and liver transplantation, using randomized clinical trials, multivariate linear and logistic regression, survival analysis, and decision tree and cost-effectiveness analyses. Several of his liver transplantation studies were funded by the National Institute of Diabetes and Digestive and Kidney Diseases, as well as the pharmaceutical industry, including several multicenter studies to investigate antiviral prophylaxis strategies and various immunosuppressive agents following liver transplantation. Dr. Brown received the Young Investigator Award from the American Society of Transplant Physicians early in his career, in 1996. In 2009, he was honored with the Senior Attending Teaching Award.